(Q30398001)

English

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 June 2017

Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). (English)

1 reference

Europe PubMed Central

21 June 2017

0 references

vector-borne disease

0 references

6

object named as

Reinhard Kurth

1 reference

Europe PubMed Central

21 June 2017

Wolfgang Poller

4

object named as

Wolfgang Poller

1 reference

Europe PubMed Central

21 June 2017

author name string

Isaac Sipo

1

1 reference

Europe PubMed Central

21 June 2017

Mathias Knauf

2

1 reference

Europe PubMed Central

21 June 2017

Henry Fechner

3

1 reference

Europe PubMed Central

21 June 2017

Oliver Planz

5

1 reference

Europe PubMed Central

21 June 2017

Stephen Norley

7

1 reference

Europe PubMed Central

21 June 2017

language of work or name

0 references

publication date

30 December 2010

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

29

1 reference

Europe PubMed Central

21 June 2017

8

1 reference

Europe PubMed Central

21 June 2017

1690-1699

1 reference

Europe PubMed Central

21 June 2017

Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Vaccination with hemagglutinin or neuraminidase DNA protects BALB/c mice against influenza virus infection in presence of maternal antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Novel linear DNA vaccines induce protective immune responses against lethal infection with influenza virus type A/H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Adenovirus as a carrier for the development of influenza virus-free avian influenza vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A novel recombinant adeno-associated virus vaccine induces a long-term humoral immune response to human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A new genetic vaccine platform based on an adeno-associated virus isolated from a rhesus macaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The cryptic life style of adeno-associated virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Long-term regulated expression of growth hormone in mice after intramuscular gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Identification of an epitope on the P and V proteins of simian virus 5 that distinguishes between two isolates with different biological characteristics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Identification of H-2Kb binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Genetic fate of recombinant adeno-associated virus vector genomes in muscle

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Adeno-associated virus vectors in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The state of the art of adeno-associated virus-based vectors in gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Adeno-associated virus-mediated gene transfer to nonhuman primate liver can elicit destructive transgene-specific T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Measuring the diaspora for virus-specific CD8+ T cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Cell-mediated protection in influenza infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Purified influenza virus nucleoprotein protects mice from lethal infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.037

7 January 2021

Identifiers

10.1016/J.VACCINE.2010.12.037

1 reference

Europe PubMed Central

21 June 2017

1 reference

Europe PubMed Central

21 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30398001&oldid=1615498103"